ADC Therapeutics SA (ADCT) Misses Q4 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates
March 18, 2021 7:00 AM EDT- Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021
- Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval
- Updated data for lead programs Lonca and Cami presented at American Society of Hematology (ASH) Annual Meeting in December 2020
- Overland ADCT BioPharma launched to develop and commercialize select products in greater China and Singapore
- Company to host conference call today at 8:30 a.m. EDT
LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:... More
